» Articles » PMID: 27193211

Selective Binding of Estrogen Receptor α to Ubiquitin Chains

Overview
Journal IUBMB Life
Date 2016 May 20
PMID 27193211
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Ubiquitin (Ub)-binding domains (UBDs) noncovalently contact the Ub modification on binding partners. Ub possesses seven lysine (K) residues (i.e., K6, K11, K27, K29, K33, K48, and K63) that can be used to form different chains based on different Ub linkage types (e.g., monoubiquitination/polyubiquitination). Thus, different Ub-based signals exist and are decoded by UBDs. Recently, we have reported the existence of two Ub binding surfaces located within the estrogen receptor α (ERα) protein. We have shown that the leucine (L) 429 and alanine (A) 430 ERα residues direct noncovalent receptor binding to K63-based Ub chains in vitro. However, mutation of L429 and A430 residues did not completely abolish the ability of ERα to associate with Ub in cell lines. Thus, we evaluated the possibility that one or both ERα Ub binding surfaces could non-covalently interact with other Ub chains. Here, we report that ERα selectively binds to specific Ub chains based on different Ub linkages and that ERα monoubiquitination requires non-covalent ERα:Ub binding. Considering the importance of the UBD:Ub interaction in the initiation and progression of many diseases (e.g., cancer), our data provide novel insights into ERα functions that could be relevant to ERα-related diseases. © 2016 IUBMB Life, 68(7):569-577, 2016.

Citing Articles

MYSM1 acts as a novel co-activator of ERα to confer antiestrogen resistance in breast cancer.

Luan R, He M, Li H, Bai Y, Wang A, Sun G EMBO Mol Med. 2024; 16(1):10-39.

PMID: 38177530 PMC: 10883278. DOI: 10.1038/s44321-023-00003-z.


Proteolysis-targeting chimeras and their implications in breast cancer.

Tecalco-Cruz A, Zepeda-Cervantes J, Ramirez-Jarquin J, Rojas-Ochoa A Explor Target Antitumor Ther. 2022; 2(6):496-510.

PMID: 36046115 PMC: 9400758. DOI: 10.37349/etat.2021.00060.


Decoding the Therapeutic Implications of the ERα Stability and Subcellular Distribution in Breast Cancer.

Tecalco-Cruz A, Macias-Silva M, Ramirez-Jarquin J, Ramirez-Jarquin U Front Endocrinol (Lausanne). 2022; 13:867448.

PMID: 35498431 PMC: 9044904. DOI: 10.3389/fendo.2022.867448.


Endocrine Resistance in Hormone Receptor Positive Breast Cancer-From Mechanism to Therapy.

Rani A, Stebbing J, Giamas G, Murphy J Front Endocrinol (Lausanne). 2019; 10:245.

PMID: 31178825 PMC: 6543000. DOI: 10.3389/fendo.2019.00245.